Two Sigma Investments LP Cuts Holdings in Kezar Life Sciences, Inc. (NASDAQ:KZR)

Two Sigma Investments LP trimmed its stake in Kezar Life Sciences, Inc. (NASDAQ:KZR) by 93.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 61,983 shares of the company’s stock after selling 839,782 shares during the quarter. Two Sigma Investments LP owned approximately 0.85% of Kezar Life Sciences worth $417,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in KZR. Peapod Lane Capital LLC purchased a new position in Kezar Life Sciences in the fourth quarter valued at about $833,000. BML Capital Management LLC purchased a new position in Kezar Life Sciences in the fourth quarter valued at about $327,000. JPMorgan Chase & Co. boosted its stake in Kezar Life Sciences by 613.8% in the fourth quarter. JPMorgan Chase & Co. now owns 11,884 shares of the company’s stock valued at $80,000 after acquiring an additional 10,219 shares during the last quarter. Dimensional Fund Advisors LP purchased a new stake in shares of Kezar Life Sciences during the 4th quarter valued at approximately $217,000. Finally, Shay Capital LLC purchased a new stake in shares of Kezar Life Sciences during the 4th quarter valued at approximately $398,000. 67.90% of the stock is currently owned by hedge funds and other institutional investors.

Kezar Life Sciences Price Performance

Shares of Kezar Life Sciences stock opened at $4.45 on Tuesday. Kezar Life Sciences, Inc. has a 52-week low of $3.62 and a 52-week high of $9.18. The stock has a market capitalization of $32.51 million, a price-to-earnings ratio of -0.34 and a beta of 0.58. The company has a fifty day moving average of $4.22 and a 200-day moving average of $5.56. The company has a debt-to-equity ratio of 0.05, a quick ratio of 7.65 and a current ratio of 7.65.

Kezar Life Sciences (NASDAQ:KZR) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($2.27) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.56) by $0.29. Equities research analysts expect that Kezar Life Sciences, Inc. will post -4.39 EPS for the current year.

Analysts Set New Price Targets

Separately, William Blair restated an “outperform” rating on shares of Kezar Life Sciences in a research note on Friday, February 28th.

Kezar Life Sciences Company Profile

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.